CHS Pharma
CHS Pharma Inc. is a biotechnology development company based in South Florida, focusing on innovative treatments for neurological, ophthalmological, and dermatological conditions. They own an intellectual property portfolio for potential treatments related to ischemic stroke, dry macular degeneration, and other age-related disorders such as Alzheimer's disease. Their mission is to develop mechanism-based treatments and create new eras of therapies in these fields, with a strong emphasis on scientific research, strategic partnerships, and investment opportunities.
Industries
Nr. of Employees
small (1-50)
Patents
Granulocyte colony-stimulating factor (GCSF) gene therapy for treating neurological diseases
US-12246074-B2
View Details
Granulocyte colony-stimulating factor (GCSF) gene therapy for treating neurological diseases
US-12246074-B2
View DetailsProducts
Ischemic stroke therapeutic candidate (multi-drug combination)
A preclinical therapeutic program consisting of a multi-drug combination designed to reduce ischemic brain injury and restore function, supported by in vivo studies and patent filings.
Dry age-related macular degeneration therapeutic candidate (RPE-protective)
Preclinical program focused on pharmacological protection of retinal pigment epithelial cells to slow progression of dry AMD, supported by publications and patent filings.
Gene therapy candidates for stroke and Alzheimer's disease
Therapeutic gene therapy constructs and associated preclinical data directed at neurodegenerative and ischemic indications, with associated patent filings.
Dermatology and oncology preclinical programs
Preclinical research outputs and publications addressing dermatological applications and cancer cell cytotoxicity/protection approaches.
Ischemic stroke therapeutic candidate (multi-drug combination)
A preclinical therapeutic program consisting of a multi-drug combination designed to reduce ischemic brain injury and restore function, supported by in vivo studies and patent filings.
Dry age-related macular degeneration therapeutic candidate (RPE-protective)
Preclinical program focused on pharmacological protection of retinal pigment epithelial cells to slow progression of dry AMD, supported by publications and patent filings.
Gene therapy candidates for stroke and Alzheimer's disease
Therapeutic gene therapy constructs and associated preclinical data directed at neurodegenerative and ischemic indications, with associated patent filings.
Dermatology and oncology preclinical programs
Preclinical research outputs and publications addressing dermatological applications and cancer cell cytotoxicity/protection approaches.
Services
Facilitation of licensing or commercialization transactions for patented therapeutic candidates and associated IP rights.
Facilitation of licensing or commercialization transactions for patented therapeutic candidates and associated IP rights.
Expertise Areas
- Translational neuroscience
- Preclinical research and animal models
- Gene therapy development
- Ophthalmic drug development
Key Technologies
- Gene therapy
- Combination pharmacotherapy
- In vivo animal models
- Retinal cell protection assays
News & Updates
A collaborative effort between FAU and Boca Raton Regional Hospital to develop stroke treatments.
FAU researchers' innovative stroke treatment has led to patent applications.
Research by FAU scientists suggests a potential treatment for strokes.
CHS Pharma to develop a stroke treatment discovered by FAU.
Settlement agreement between CHS Pharma and the Town of Jupiter.
Funding received by FAU to develop stroke treatments.
A collaborative effort between FAU and Boca Raton Regional Hospital to develop stroke treatments.
FAU researchers' innovative stroke treatment has led to patent applications.
Research by FAU scientists suggests a potential treatment for strokes.
CHS Pharma to develop a stroke treatment discovered by FAU.
Settlement agreement between CHS Pharma and the Town of Jupiter.
Funding received by FAU to develop stroke treatments.